Oscar Health stock rises 2% on strong earnings beat and raised outlook
Oscar Health (OSCR) reported Q3 earnings of $0.49 per share, beating estimates by $0.63, with revenue of $5.14B, up 72% YoY. The company raised its 2026 revenue guidance to $19.0B-$19.3B and increased its earnings from operations outlook. Shares rose 2.59% in pre-market trading. Membership grew to 2.69M, up from 2.12M a year earlier.
How this was made
The 30-second read
Why it matters
Earnings beat and guidance raise suggest stronger enrollment and cost control, likely boosting the stock.
Market read
The earnings surprise and upgraded outlook provide a clear catalyst for short‑term trading.
What to watch
Potential regulatory changes to the ACA could affect future growth.
Background
Oscar Health is a publicly traded health‑insurance company focused on individual markets under the ACA.
Ticker impact
Oscar Health reported Q3 earnings beat and raised full‑year revenue and earnings guidance, prompting a 2.6% pre‑market price rise.
upward pressure as the market prices in the earnings beat and higher guidance
The beat and guidance lift expectations for profitability and cash flow, supporting a near‑term rally.
Market effects
Improves outlook for health‑insurance and digital‑health peers.
Positive for U.S. health‑tech stocks.
Limited to U.S. markets; no direct global effect.
Counterpoint
If the guidance increase proves unsustainable, the stock could face a pull‑back.
Key entities
- ExecutiveMark Bertolini
CEO of Oscar Health who announced the results.
